Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on
allergy vaccination, today announces positive results from its Pollinex Quattro Ragweed
Phase III study, R301, the second largest controlled allergy vaccine study ever
conducted. The study met its primary efficacy endpoint and demonstrated that Pollinex
Quattro Ragweed has statistically significant clinical benefits over placebo. On 14 May
2008, Allergy Therapeutics announced that its earlier study, Pollinex Quattro Grass
(“G301”), had met its primary efficacy endpoint in what is still the largest allergy vaccine
study ever conducted.

Allergy Therapeutics intends to use the results of the ragweed study to support a
Marketing Approval Application in Canada with a submission planned for 2009. Allergy
Therapeutics believes that Pollinex Quattro has the potential to transform the treatment
of allergy, changing the lives of patients and providing an important new tool for the
specialists who treat them. The worldwide market for allergy treatments is estimated to
be in excess of $10 billion.

Download full PDF here